Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
about
Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.High and low frequency subharmonic imaging of angiogenesis in a murine breast cancer modelThe antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Nanobubble ultrasound contrast agents for enhanced delivery of thermal sensitizer to tumors undergoing radiofrequency ablationA comparative evaluation of ultrasound molecular imaging, perfusion imaging, and volume measurements in evaluating response to therapy in patient-derived xenograftsContrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study.Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts.A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculatureDifferentiation of benign periablational enhancement from residual tumor following radio-frequency ablation using contrast-enhanced ultrasonography in a rat subcutaneous colon cancer model.Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubblesMolecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.Contrast-enhanced ultrasonography of hepatocellular carcinoma: correlation between quantitative parameters and histological grading.Quantitative analysis of contrast-enhanced ultrasonography: differentiating focal nodular hyperplasia from hepatocellular carcinomaCorrelation of ultrasound contrast agent derived blood flow parameters with immunohistochemical angiogenesis markers in murine xenograft tumor modelsNon-invasive molecular imaging for preclinical cancer therapeutic development.Dynamic contrast-enhanced ultrasound for quantification of tissue perfusion.Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response.Assessment of tissue perfusion by contrast-enhanced ultrasound.Comparison of photoacoustically derived hemoglobin and oxygenation measurements with contrast-enhanced ultrasound estimated vascularity and immunohistochemical staining in a breast cancer model.Quantitative assessment of tumor blood flow changes in a murine breast cancer model after adriamycin chemotherapy using contrast-enhanced destruction-replenishment sonography.Reproducibility of Contrast-Enhanced Ultrasound in Mice with Controlled Injection.
P2860
Q30365404-1CB01C13-B9EE-49E9-9E4B-E90E40DD895BQ30375548-CF9F5E57-D4A8-4A36-AE70-7BD76E5C4D57Q30409780-F02C009C-E202-45D5-B5B0-1498FD6A9A55Q30410530-504C4C8D-B8FB-4D58-ADAA-87E2A7D3575DQ30412053-5E87CC8D-D419-4300-A6F6-05B57360F595Q30454165-C93B935F-F312-4B70-A55A-A9F2D0EFB85CQ34536116-1A761A7D-3015-4599-8B44-B09D4154D106Q34613460-7E08E341-4D41-4934-A27E-CF33733FD42DQ35118263-72102778-6285-466F-94E9-6789F8E94AD3Q35760144-30AD0850-6C16-4F33-BB06-2CA9D9582DD3Q36158355-8E7AB0F2-A461-4F8F-A854-555671A22A49Q36158757-1F6ED0D8-2D95-4722-AC86-D746495F7113Q36365545-71989A35-8D85-4B81-BD0B-DAA4727BAE89Q36715988-BC939DDC-4AB6-4372-AD5C-3465FD90CBE3Q36966777-B6304FB8-F50C-44A0-9A9E-8E9832067E7DQ38089102-DF4A6F2A-46AE-40A8-B50C-6BA729D83953Q38329582-E552FA50-0F1A-4BD2-969B-B6948AB1B9B2Q41667212-EC18014C-0B73-480D-A54A-1A7DE6D8C588Q51650477-29825230-69EE-4F94-B4BF-4C20E397E1C4Q53074116-6BE41205-01D6-4402-993D-4E7B38C5EE91Q53115803-2F3E58AE-3397-45AB-B661-07D3C31E1ABFQ53122944-D4AC7187-AA26-4557-B842-5BA93C31EF78
P2860
Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@en
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@nl
type
label
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@en
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@nl
prefLabel
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@en
Noninvasive contrast-enhanced ...... scontinuing anti-VEGF therapy.
@nl
P2093
P50
P356
P1433
P1476
Noninvasive contrast-enhanced ...... iscontinuing anti-VEGF therapy
@en
P2093
Aymeric Guibal
Eva Comperat
Jean Louis Golmard
Laurent Taillade
Olivier Rixe
Sébastien Mulé
Yasmina Badachi
P304
P356
10.1148/RADIOL.09090728
P407
P577
2010-02-01T00:00:00Z